Autopsy report · NCT01201538
A Study of Nilotinib in Growing Vestibular Schwannomas
Cause of deathStaffing, sites or logistics
“Study PI passed away We had trouble recruiting for the drug arm”
Life of this trial
- Registered 1 month before it started.
- Ran for about 3 years before it stopped.
- 2 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Conditions
- Growing Vestibular Schwannomas
- Interventions
- Nilotinib
- Participants
- 2
- Sites
- 2
- Countries
- Canada
Trials that died the same way
- Aliskiren and Renin Inhibition in Diastolic Heart Failure
“Difficulty in recruiting patients and then the PI left the institution” - Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
“Drug expired and access to additional supply ended. PI left the institution shortly afterwards and the study will not be re-activated. Only 4 patients were enrolled.” - Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
“PI Determination - Slow recruitment, funding concerns, poor response to treatment” - Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8
“PI left institution, end of funding, clinic relocation, recruitment issues” - Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever
“Unable to recruit sufficient participants due to lack of funding; PI has left the institution.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.